• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

进行群体药代动力学分析时,我们需要完整的依从性数据吗?

Do we need full compliance data for population pharmacokinetic analysis?

作者信息

Girard P, Sheiner L B, Kastrissios H, Blaschke T F

机构信息

Department of Pharmacy, School of Pharmacy, University of California, San Francisco, USA.

出版信息

J Pharmacokinet Biopharm. 1996 Jun;24(3):265-82. doi: 10.1007/BF02353671.

DOI:10.1007/BF02353671
PMID:8970015
Abstract

For population pharmacokinetic analysis of multiple oral doses one of the key issues is knowing as precisely as possible the dose inputs in order to fit a model to the input-output (dose-concentration) relationship. Recently developed electronic monitoring devices, placed on pill containers, permit precise records to be obtained over months, of the time/date opening of the container. Such records are reported to be the most reliable measurement of drug taking behavior for ambulatory patients. To investigate strategies for using and summarizing this new abundant information, a Markov chain process model was developed, that simulates compliance data from real data from electronically monitored patients, and data simulations and analyses were conducted. Results indicate that traditional population pharmacokinetic analysis methods that ignore actual dosing information tend to estimate biased clearance and volume and markedly overestimate random interindividual variability. The best dosing information summarization strategies consist of initially estimating population pharmacokinetic parameters, using no covariates and only a limited number of dose records, the latter chosen based on an a priori estimate of the half-life of the drug in the compartment of interest; then resummarizing the dose records using either population or individual posterior Bayes parameter estimates from the first population fit; and finally reestimating the population parameters using the newly summarized dose records. Such summarization strategies yield the same parameter estimates as using full dosing information records while reducing by at least 75% the CPU time needed for a population pharmacokinetic analysis.

摘要

对于多次口服剂量的群体药代动力学分析,关键问题之一是尽可能精确地了解剂量输入情况,以便使模型能够拟合输入-输出(剂量-浓度)关系。最近研发的置于药瓶上的电子监测装置,能够获取数月内药瓶开启时间/日期的精确记录。据报道,此类记录是门诊患者用药行为最可靠的测量方式。为了研究使用和汇总这些丰富新信息的策略,开发了一种马尔可夫链过程模型,该模型可模拟来自电子监测患者真实数据的依从性数据,并进行了数据模拟与分析。结果表明,忽略实际给药信息的传统群体药代动力学分析方法往往会估计出有偏差的清除率和容积,并显著高估个体间的随机变异性。最佳的给药信息汇总策略包括:首先在不使用协变量且仅使用有限数量剂量记录的情况下估计群体药代动力学参数,后者基于对感兴趣隔室内药物半衰期的先验估计来选择;然后使用首次群体拟合得到的群体或个体后验贝叶斯参数估计值重新汇总剂量记录;最后使用新汇总的剂量记录重新估计群体参数。这种汇总策略产生的参数估计值与使用完整给药信息记录时相同,同时将群体药代动力学分析所需的CPU时间减少至少75%。

相似文献

1
Do we need full compliance data for population pharmacokinetic analysis?进行群体药代动力学分析时,我们需要完整的依从性数据吗?
J Pharmacokinet Biopharm. 1996 Jun;24(3):265-82. doi: 10.1007/BF02353671.
2
Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.基于药代动力学的口服抗癌化疗药物患者依从性估计:计算机模拟评估。
Clin Pharmacokinet. 2009;48(6):359-69. doi: 10.2165/00003088-200948060-00002.
3
Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.利匹韦林在接受利匹韦林/替诺福韦/恩曲他滨单片复方制剂治疗的HIV-1感染患者中的群体药代动力学。
Eur J Clin Pharmacol. 2018 Apr;74(4):473-481. doi: 10.1007/s00228-017-2405-1. Epub 2018 Jan 26.
4
A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.一种用于估计甲型血友病患者凝血因子 VIII 个体药代动力学参数的有限采样策略。
Ther Drug Monit. 2007 Feb;29(1):20-6. doi: 10.1097/FTD.0b013e3180311384.
5
Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.基于稳态假设的群体药代动力学与洛匹那韦、阿扎那韦、依非韦伦和依曲韦林电子监测依从性的比较:一项回顾性研究。
Ther Drug Monit. 2016 Aug;38(4):506-15. doi: 10.1097/FTD.0000000000000297.
6
Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.多柔比星的群体药代动力学:成人和 3 岁以上儿童 NONMEM 模型的建立。
Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63. doi: 10.1007/s00280-013-2069-1. Epub 2013 Jan 13.
7
Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.通过蒙特卡洛模拟,利用健康受试者单次静脉给药后收集的药代动力学(PK)数据和群体PK建模,选择WST11的给药方案。
J Pharm Sci. 2007 Dec;96(12):3444-56. doi: 10.1002/jps.21018.
8
On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data.关于重复测量药代动力学数据的采样时间记录和参数估计
J Pharmacokinet Biopharm. 1996 Dec;24(6):637-50. doi: 10.1007/BF02353484.
9
Role of patient compliance in clinical pharmacokinetics. A review of recent research.患者依从性在临床药代动力学中的作用。近期研究综述。
Clin Pharmacokinet. 1994 Sep;27(3):202-15. doi: 10.2165/00003088-199427030-00004.
10
[Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects].[治疗监测:分析、药代动力学及临床方面]
Acta Clin Belg. 1999;53 Suppl 1:2-12.

引用本文的文献

1
Historical Use of Markov Model and Posterior Predictive Checks in Pharmacometrics.马尔可夫模型和后验预测检验在药物计量学中的历史应用。
CPT Pharmacometrics Syst Pharmacol. 2025 May;14(5):817-818. doi: 10.1002/psp4.70031. Epub 2025 Apr 8.
2
Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease.利用数学模型分析镰状细胞病患者羟基脲治疗的不依从性。
CPT Pharmacometrics Syst Pharmacol. 2023 Jun;12(6):748-757. doi: 10.1002/psp4.12945. Epub 2023 May 16.
3
Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis.

本文引用的文献

1
Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring.口服他莫昔芬的依从性:患者自我报告、药丸计数与微电子监测的比较
J Clin Oncol. 1993 Jun;11(6):1189-97. doi: 10.1200/JCO.1993.11.6.1189.
2
A pharmacokinetic perspective on medicament noncompliance.
Clin Pharmacol Ther. 1993 Sep;54(3):242-4. doi: 10.1038/clpt.1993.143.
3
The estimation of population pharmacokinetic parameters using an EM algorithm.使用期望最大化(EM)算法估计群体药代动力学参数。
HIV 暴露前预防用药的个体化依从性基准
AIDS Res Hum Retroviruses. 2021 Jun;37(6):421-428. doi: 10.1089/AID.2020.0108. Epub 2020 Dec 10.
4
Handling Missing Dosing History in Population Pharmacokinetic Modeling: An Extension to MDM Method.处理群体药代动力学建模中的缺失剂量史:MDM 方法的扩展。
CPT Pharmacometrics Syst Pharmacol. 2019 Jan;8(1):39-49. doi: 10.1002/psp4.12374. Epub 2019 Jan 17.
5
Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?移植受者他克莫司的群体药代动力学:我们从个体间变异性的来源中学到了什么?
J Clin Pharmacol. 2019 Mar;59(3):309-325. doi: 10.1002/jcph.1325. Epub 2018 Oct 29.
6
Medication Routines and Adherence Among Hypertensive African Americans.高血压非裔美国人的用药方案与依从性
J Clin Hypertens (Greenwich). 2015 Sep;17(9):668-72. doi: 10.1111/jch.12566. Epub 2015 May 7.
7
A hybrid Markov chain-von Mises density model for the drug-dosing interval and drug holiday distributions.一种用于药物给药间隔和药物假期分布的混合马尔可夫链-冯·米塞斯密度模型。
AAPS J. 2015 Mar;17(2):427-37. doi: 10.1208/s12248-014-9713-5. Epub 2015 Jan 22.
8
Methods to detect non-compliance and reduce its impact on population PK parameter estimates.检测不依从性并降低其对群体 PK 参数估算影响的方法。
J Pharmacokinet Pharmacodyn. 2014 Jun;41(3):279-89. doi: 10.1007/s10928-014-9364-2. Epub 2014 Jun 21.
9
An examination of 1-year adherence and persistence rates to antiepileptic medication in children with newly diagnosed epilepsy.新诊断癫痫患儿抗癫痫药物1年依从率和持续治疗率的调查。
J Pediatr Psychol. 2015 Jan-Feb;40(1):66-74. doi: 10.1093/jpepsy/jsu010. Epub 2014 Mar 19.
10
Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.在没有可靠给药史的情况下估算替诺福韦的群体药代动力学参数,并应用模拟策略追溯给药史。
J Clin Pharmacol. 2014 Feb;54(2):150-60. doi: 10.1002/jcph.221. Epub 2013 Nov 30.
Comput Methods Programs Biomed. 1993 Sep;41(1):9-16. doi: 10.1016/0169-2607(93)90062-p.
4
New strategies in drug development and clinical evaluation: the population approach. Commentary on an action for co-operative research.
Eur J Clin Pharmacol. 1993;45(2):93-4. doi: 10.1007/BF00315486.
5
Designing an optimal experiment for Bayesian estimation: application to the kinetics of iodine thyroid uptake.
Stat Med. 1994 Jan 30;13(2):185-96. doi: 10.1002/sim.4780130209.
6
Estimating bioavailability when clearance varies with time.
Clin Pharmacol Ther. 1994 Jun;55(6):623-37. doi: 10.1038/clpt.1994.79.
7
Role of patient compliance in clinical pharmacokinetics. A review of recent research.患者依从性在临床药代动力学中的作用。近期研究综述。
Clin Pharmacokinet. 1994 Sep;27(3):202-15. doi: 10.2165/00003088-199427030-00004.
8
Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project.冠状动脉药物项目中治疗依从性和胆固醇反应对死亡率的影响。
N Engl J Med. 1980 Oct 30;303(18):1038-41. doi: 10.1056/NEJM198010303031804.
9
An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies.治疗试验中群体药代动力学的评估。第一部分。方法学比较。
Clin Pharmacol Ther. 1986 Jun;39(6):605-12. doi: 10.1038/clpt.1986.107.
10
How often is medication taken as prescribed? A novel assessment technique.药物按处方服用的频率如何?一种新颖的评估技术。
JAMA. 1989 Jun 9;261(22):3273-7.